Genmab Commences Tender Offer for All Issued and Outstanding Common Shares of Merus N.V. Media ReleaseCOPENHAGEN, Denmark; October 21, 2025 (Nasdaq: GMAB) (“Genmab”) announced today that it is commencing, through a wholly owned subsidiary, Genmab Holding II B.V. (“Purchaser”), a cash tender offer (the “Offer”) to purchase all of the issued and outstanding common shares (“Common Shares”) of (Nasdaq: MRUS) (“Merus”) for $97.00 per Common Share in cash (the “Offer Consideration”), less any applicable withholding taxes and without interest. The Offer is being made pursuant to the previously...
Genmab Announces New Data Demonstrating Investigational Rinatabart Sesutecan (Rina-S®) Achieved Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer Media Release COPENHAGEN, Denmark; October 18, 2025 Updated data from the Phase 1/2 RAINFOL™-01 trial showed rinatabart sesutecan (Rina-S®) 100 mg/m2 demonstrated 50% confirmed objective response rate (ORR), including two complete responses (CR), regardless of FRα expressionA Phase 3 trial in endometrial cancer is underwayU.S. FDA recently granted Breakthrough Therapy Designation to Rina-S for advanced endometria...
Scorpio Tankers Inc. Announces that on October 30, 2025, the Company Plans to Issue Its Third Quarter 2025 Results and Have a Conference Call MONACO, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Scorpio Tankers Inc. (NYSE: ) ("Scorpio Tankers," or the "Company") announced today that on Thursday, October 30, 2025, the Company plans to issue its third quarter 2025 earnings press release in the morning (Eastern Daylight Time) and host a conference call at 9:00 AM Eastern Daylight Time and 2:00 PM Central European Time. Conference Call Information Title: Scorpio Tankers Inc. Third Quarter 2025 Confere...
Transocean Ltd. Announces Early Tender Results and Upsizing of Cash Tender Offer STEINHAUSEN, Switzerland, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Transocean Ltd. (NYSE: RIG), a Swiss corporation (“Transocean”), announced the early results, as of 5:00 p.m. New York City time on October 14, 2025 (the “Early Tender Date”), of the previously announced cash tender offer (the “Tender Offer”) by Transocean International Limited, a Bermuda exempted company limited by shares (the “Company”) and a wholly owned subsidiary of Transocean, to purchase up to an aggregate principal amount of the outstanding 7...
Transocean Ltd. Provides Quarterly Fleet Status Report STEINHAUSEN, Switzerland, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Transocean Ltd. (NYSE: RIG) today issued a quarterly Fleet Status Report that provides the current status of, and contract information for, the company’s fleet of offshore drilling rigs. This quarter’s report includes the following updates: Deepwater Atlas – Customer exercised a 365-day option in the U.S. Gulf at a dayrate of $635,000. Deepwater Mykonos – Customer exercised a 30-day option in Brazil. The aggregate incremental backlog associated with these fixtures is appr...
Transocean Ltd. Announces Third Quarter 2025 Earnings Release Date STEINHAUSEN, Switzerland, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Transocean Ltd. (NYSE: RIG) announced today that it will report earnings for the third quarter 2025 on Wednesday, October 29, 2025, after the close of trading on the New York Stock Exchange. The company will conduct a teleconference starting at 9 a.m. EDT, 2 p.m. CET, on Thursday, October 30, 2025. Individuals who wish to participate in the teleconference should dial approximately 15 minutes prior to the scheduled start time and refer to conference code 234878....
We initiate coverage on Carlsberg with an Outperform recommendation and a DKK 985 TP, valuing the brewer at 12-month EV/EBITDA of 10.7x, EV/EBIT of 14.7x, and P/E of 15.8x. All three European listed brewers in our coverage universe have an attractive valuation. However, we prefer Carlsberg because of its geographical exposure – with a focus on less volatile Europe and Asia – and because of its 30% soft drink exposure, which we conclude is synergistic to beer, adds to growth, and is less debated ...
Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2025 Company Announcement Net sales of DARZALEX® in the third quarter of 2025 totaled USD 3,672 millionGenmab receives royalties on worldwide net sales from Johnson & Johnson (J&J, legal entity Janssen Biotech, Inc.) COPENHAGEN, Denmark; October 14, 2025 – (Nasdaq: GMAB) announced today that worldwide net trade sales of DARZALEX (daratumumab), including sales of the subcutaneous (SC) product (daratumumab and hyaluronidase-fihj, sold under the tradename DARZALEX FASPRO® in the U.S.), as reported by J&J were USD 3,...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.